In this article in Neuro Oncology, Dr Kieran and others from Dana-Farber Cancer Institute and Harvard Medical School report the results of the RAD001 clinical trial in pediatric patients.  They show that treatment with RAD001 was well tolerated in patients with recurrent or progressive low-grade gliomas, and that incorporation of this drug into front line treatment should be considered.